Rob A. A. van Kollenburg,1 Luigi A. M. J. G. van Riel,1 Jorg R. Oddens,1 Theo M. de Reijke,1 Ton A. G. J. M. van Leeuwen,1 Harrie P. Beerlage,1 Daniel M. de Bruinhttps://orcid.org/0000-0003-3047-36371
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Transperineal laser ablation (TPLA) is a novel minimal invasive treatment of benign prostatic obstruction. TPLA can be performed in an outpatient setting under local anesthesia with optional conscious sedation. The mechanism is based on laser ablation resulting in coagulative necrosis, which is induced by the laser light of 1064 nm. Laser light is delivered in the prostate trough transperineal placed needles. This study treated 20 men using TPLA to evaluate safety, feasibility, and voiding outcomes. TPLA has the potential to become an alternative for standard treatments with urethral approach that require general or spinal anesthesia and hospital admittance.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Rob A. A. van Kollenburg, Luigi A. M. J. G. van Riel, Jorg R. Oddens, Theo M. de Reijke, Ton A. G. J. M. van Leeuwen, Harrie P. Beerlage, Daniel M. de Bruin, "Transperineal laser ablation treatment for lower urinary tract symptoms in men: outcomes of a pilot study," Proc. SPIE PC12353, Advanced Photonics in Urology 2023, PC1235304 (17 March 2023); https://doi.org/10.1117/12.2650309